It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
During HIV infection, cell-to-cell transmission results in endosomal uptake of the virus by target CD4+ T cells and potential exposure of the viral ssRNA genome to endosomal Toll-like receptors (TLRs). TLRs are instrumental in activating inflammatory responses in innate immune cells, but their function in adaptive immune cells is less well understood. Here we show that synthetic ligands of TLR8 boosted T cell receptor signaling, resulting in increased cytokine production and upregulation of surface activation markers. Adjuvant TLR8 stimulation, but not TLR7 or TLR9, further promoted T helper cell differentiation towards Th1 and Th17. In addition, we found that endosomal HIV induced cytokine secretion from CD4+ T cells in a TLR8-specific manner. TLR8 engagement also enhanced HIV-1 replication and potentiated the reversal of latency in patient-derived T cells. The adjuvant TLR8 activity in T cells can contribute to viral dissemination in the lymph node and low-grade inflammation in HIV patients. In addition, it can potentially be exploited for therapeutic targeting and vaccine development.
Manipulation of Toll-like receptors (TLRs) affects HIV-1 infection and latency reversal. Here, the authors show that HIV-1 is endocytosed and recognized by TLR8 in human primary CD4+T cells and that TLR8 stimulation induces an inflammatory response that promotes HIV-1 replication and reversal of latency.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Infectious Diseases, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560)
2 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393)
3 Tsinghua University, School of Pharmaceutical Sciences, Tsinghua University—Peking University Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178) ; University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
4 University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
5 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Medical Microbiology, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560)
6 University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921) ; Oslo University Hospital, Department of Cancer Immunology, Institute of Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485) ; University of Oslo, K.G. Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
7 Tsinghua University, School of Pharmaceutical Sciences, Tsinghua University—Peking University Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
8 Norwegian University of Science and Technology, Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393) ; St. Olavs Hospital, Department of Infectious Diseases, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560) ; University of Oslo and Oslo University Hospital, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)